冠心病合并房颤的抗栓治疗

摘要/Abstract

摘要： 冠心病患者常合并房颤,对这类患者,尤其是需要放置冠状动脉支架的房颤患者,抗血栓治疗是一个难题。需要权衡中风、支架血栓和出血的风险。本文主要综述冠心病合并房颤患者的抗血栓治疗。

Abstract: Antithrombotic therapy is a real challenge in atrial fibrilation patients with coronary heart disease, especially in patients undergoing coronary stenting on triple therapy, need to balance the risk of bleeding complications and the benefits of reducing atherothrombotic events.This article will focus on antithrombotic therapy in atrial fibrilation patients with coronary heart disease.

Key words: Atrial fibrilation, Coronary heart disease, Antithrombotic therapy

中图分类号:

R541

吴美华. 冠心病合并房颤的抗栓治疗[J]. 中国临床药理学与治疗学, 2012, 17(8): 957-960.

WU Mei-hua. Antithrombotic therapy in atrial fibrilation patients with coronary heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 957-960.

参考文献

[1] McNamara RL, Tamariz LJ, Segal JB,et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography[J]. Ann Intern Med,2003,139(12): 1018-1033.
[2] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med,2007,146(12): 857-867.
[3] Connolly S, Pogue J, Hart R,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial[J]. Lancet,2006,367(9526): 1903-1912.
[4] Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J]. N Engl J Med,2009,360(20): 2066-2078.
[5] Connolly SJ, Ezekowitz MD, Yusuf S,et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12): 1139-1151.
[6] Beasley BN, Unger EF, Temple R. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran[J]. N Engl J Med,2011, 364(19):1788-1790.
[7] Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly[J]. N Engl J Med, 2012,366(9):864-866.
[8] Patel MR, Mahaffey KW, Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med. 2011,365(10):883-91.
[9] Granger CB, Alexander JH, McMurray JJ,et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992.
[10] Fuster V, Ryden LE, Cannom DS,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [J]. Circulation. 2006,114(7): 700-752.
[11] Singer DE, Albers GW, Dalen JE,et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. Chest. 2008,133(6 Suppl): 546S-592S.
[12] Lip GY, Nieuwlaat R, Pisters R,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest,2010,137(2): 263-272.
[13] King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2005 Writing Committee Members. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee [published correction appears in Circulation. 2008;117:e161]. Circulation, 2008,117: 261-295.
[14] Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J]. Circulation,2006,114(8): 774-782.
[15] Konstantino Y, Iakobishvili Z, Porter A, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes[J]. Cardiology,2006,105(2): 80-85.
[16] Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline[J]. Chest,2006,130(6): 1823-1827.
[17] Rubboli A, Colletta M, Herzfeld J, et al. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention[J]. Coron Artery Dis,2007,18(3): 193-199.
[18] Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent[J] ? Eur Heart J,2007,28(14): 1717-1722.
[19] Rogacka R, Chieffo A, Michev I, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation[J]. JACC Cardiovasc Interv,2008,1(1): 56-61.
[20] Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy[J]. Am J Cardiol,2008,102(12): 1618-1623.
[21] Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data[J]. Lancet,2009,374(9706) :1967-1974.
[22] Schulman S, Beyth RJ, Kearon C,et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment[J]. Chest,2008,133: 257S-298S.
[23] Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180: 713-718.
[24] Ho PM, Maddox TM, Wang L,et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J]. JAMA, 2009,301(9): 937-944.
[25] O'Donoghue ML, Braunwald E, Antman EM,et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials[J]. Lancet,2009,374(9694): 989-997.